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With great interest, we read the recent article by Besse-
reau et al. [1] in “international Maritime Health” describing 
patient characteristics and clinical outcomes of French 
divers treated for decompression sickness (DCS). Intere-
stingly, a significant proportion of reported diving accident 
victims (38% of n = 49) received aspirin during the initial 
first aid treatment. The administration of aspirin in suspec-
ted DCS is in accordance with the directives of the French 
national diving federation (FFESSM, Fédération françaire 
d’études et de sports sous-marins) and French practice 
in DCS treatment in hyperbaric facilities [2]. However, the 
use of aspirin is not included in international consensus 
statements on adjunctive interventions to recompression 
treatment [3]. 
There is a clear theoretical rationale for the use of aspi-
rin, as it has been shown that nitrogen bubbles interact 
with thrombocytes leading to thrombocyte adhesion and 
activation, which is thought to contribute to microvessel 
obstruction in DCS [4]. In preclinical models, inhibition of 
thrombocyte aggregation using aspirin or clopidogrel attenu-
ates the clinical course of DCS [5]. However, proper clinical 
trials investigating the use thrombocyte inhibitors have not 
been performed so far.
Importantly, administration of aspirin could theoretically 
also complicate DCS due to the increased bleeding propen-
sity. Besides possible bleeding complications associated 
with barotrauma during recompression, particular concern 
arises from historical observations of central nervous sys-
tem bleedings in severe DCS [6].
We would greatly appreciate it if Bessereau et al. [1] 
provided further details on the use of aspirin in their co-
hort. It is unclear which proportion of divers was treated 
with aspirin during DCS treatment once admitted to the 
hyperbaric facility. Particularly, an additional analysis of 
their data comparing divers (initially) treated with aspirin vs. 
those who were not treated with aspirin would be valuable. 
Also, it is important to report on any bleeding complications, 
or absence thereof, observed during DCS or recompression 
treatment in divers using aspirin, for future reference. Such 
retrospective analysis of French experience with aspirin 
in DCS victims could pave the way for a randomized trial 
inves tigating the use of antiplatelet drugs in DCS treatment. 
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